Cardiovascular Risk Reduction in Atrial Fibrillation Trial

  • End date
    Aug 25, 2025
  • participants needed
  • sponsor
    Beijing Anzhen Hospital
Updated on 25 June 2021
coronary artery disease
ejection fraction
heart failure
systolic blood pressure
atrial fibrillation
myocardial infarction
acute coronary syndrome
coronary artery bypass graft
glycosylated hemoglobin
antihypertensive drugs
antihypertensive agents
transient ischemic attack
persistent atrial fibrillation
anticoagulation therapy
fasting plasma glucose
stress test


Atrial fibrillation (AF) is a serious public health problem because of its increasing incidence and prevalence in the aging population. AF is associated with elevated risks of death, stroke, coronary event, heart failure, cognitive decline, and chronic kidney disease. To identify preventive interventions for major cardiovascular events beyond effective anticoagulation should be a major priority in the treatment of AF patients. The CRAFT study is a 2-arm, multicenter, randomized clinical trial designed to test whether intensive blood pressure control will reduce the risk of major cardiovascular events in AF patients.


The CRAFT trial will include approximately 6000 AF patients with home SBP 125-154 mmHg and at least another cardiovascular risk factor. The trial aims to compare the effects of randomization to a treatment program of an intensive SBP goal (target home SBP <120mmHg) with randomization to a treatment program of a standard goal (target home SBP <135mmHg). The primary hypothesis is that cardiovascular event rates will be lower in the intensive arm. Participants will be recruited over a 3-year period at approximately 100 to 150 clinical centres and the first patient will be followed for up to 5 years.

Condition arterial hypertension, High Blood Pressure (Hypertension), Arrhythmia, high blood pressure, Atrial Fibrillation (Pediatric), Dysrhythmia, Hypertension, Atrial Fibrillation, High Blood Pressure (Hypertension - Pediatric), Elevated Blood Pressure, Vascular Diseases, Diabetes and Hypertension
Treatment Intensive BP control, Standard BP control
Clinical Study IdentifierNCT04347330
SponsorBeijing Anzhen Hospital
Last Modified on25 June 2021


How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note